Fibrillar amyloid correlates of preclinical cognitive decline
نویسندگان
چکیده
منابع مشابه
Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
We perform a large-scale meta-analysis of 51 peer-reviewed 3xTg-AD mouse publications to compare Alzheimer's disease (AD) quantitative clinical outcome measures, including amyloid-β (Aβ), total tau, and phosphorylated tau (pTau), with cognitive performance in Morris water maze (MWM) and Novel Object Recognition (NOR). "High" levels of Aβ (Aβ40, Aβ42) showed significant but weak trends with cog...
متن کاملPreventing cognitive decline in preclinical Alzheimer's disease.
Alzheimer's disease (AD) is a chronic neurodegenerative disease leading to cognitive decline, dementia, and ultimately death. Despite extensive R&D efforts, there are no diseases modifying treatments for AD available. The stage in which patients receive a clinical diagnosis of probable AD may be too late for disease modifying pharmacotherapy. Prevention strategies may be required to successfull...
متن کاملAmyloid deposition, hypometabolism, and longitudinal cognitive decline.
OBJECTIVE Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) population, we examined (1) cross-sectional relationships between amyloid deposition, hypometabolism, and cognition, and (2) associations between amyloid and hypometabolism measurements and longitudinal cognitive measurements. METHODS We examined associations between mean cortical florbetapir uptake, mean (18) F-...
متن کاملPlasma ß-amyloid and cognitive decline.
OBJECTIVES To determine if plasma β-amyloid (Aβ) levels (1) can be linked to specific cognitive changes that constitute conversion to Alzheimer disease (AD) and (2) correspond to cognitive change independent of dementia. DESIGN Longitudinal study including 3 visits during approximately 4¹/₂ years (2000-2006). SETTING Northern Manhattan community. PARTICIPANTS Eight hundred eighty individu...
متن کاملSubtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
The NIA-AA criteria for "preclinical" Alzheimer's disease (AD) propose a staging method in which AD biomarkers follow an invariable temporal sequence in accordance with the amyloid cascade hypothesis. However, recent findings do not align with the proposed temporal sequence and "subtle cognitive decline," which has not been definitively operationalized, may occur earlier than suggested in precl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Alzheimer's & Dementia
سال: 2014
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.01.009